#moderna
moderna
7,693 ຄັ້ງທີ່ເບິ່ງ
56 ກຳລັງສົນທະນາ
ມາແຮງ
ຫຼ້າສຸດ
·
--
🧬 $MRNAB RISES 6.42% — BIOTECH EXPOSURE IS ON THE MOVE!
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
🧬 $MRNAB RISES 6.42% — BIOTECH EXPOSURE IS ON THE MOVE!
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
1
45
·
--
$MRNAB IS MOVING UP — CAN BUYERS TURN A STEADY GAIN INTO A BIGGER MOVE?
Moderna bStocks ($MRNAB) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
$MRNAB IS MOVING UP — CAN BUYERS TURN A STEADY GAIN INTO A BIGGER MOVE?
Moderna bStocks ($MRNAB ) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
Moderna bStocks ($MRNAB ) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
80
·
--
ສັນຍານກະທິງ
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
{future}(MRNAUSDT)
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
1
390
·
--
好数据出炉，股价先崩26%：Moderna癌症疫苗，医生说好，钱说不
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
好数据出炉，股价先崩26%：Moderna癌症疫苗，医生说好，钱说不
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
291
·
--
【美股盘前异动 - Moderna $MRNAB 】
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
{spot}(MRNABUSDT)
#生物科技 #moderna #币安神算子
【美股盘前异动 - Moderna $MRNAB 】
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
#生物科技 #moderna #币安神算子
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
#生物科技 #moderna #币安神算子
317
·
--
ສັນຍານໝີ
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
{spot}(MRNABUSDT)
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
97
·
--
Moderna 收在242美元，华尔街平均目标价才101，股价是目标价的2.4倍，周六数据前我不追
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
Moderna 收在242美元，华尔街平均目标价才101，股价是目标价的2.4倍，周六数据前我不追
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
423
·
--
ສັນຍານກະທິງ
🚨 سيتم إدراج شركة "موديرنا" (Moderna) في مؤشر "ناسداك 100" (Nasdaq 100) بعد أن سجل سهمها ارتفاعاً هائلاً تجاوز 600% في عام 2026.
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
{spot}(MRNABUSDT)
🚨 سيتم إدراج شركة "موديرنا" (Moderna) في مؤشر "ناسداك 100" (Nasdaq 100) بعد أن سجل سهمها ارتفاعاً هائلاً تجاوز 600% في عام 2026.
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
1
39
·
--
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
MRNAonAlpha
MRNAUS-0,25%
93
·
--
ສັນຍານກະທິງ
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
{future}(TUTUSDT)
$ZEC
{future}(ZECUSDT)
{spot}(MRNABUSDT)
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
3
380
·
--
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
{future}(TRUMPUSDT)
{alpha}(560x01486675da0764ee780ea7cb65c33062e9b2d28c)
$ZEC
{future}(ZECUSDT)
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
1
239
·
--
هذا أمر مذهل. ارتفع سهم شركة "موديرنا" (Moderna) بنحو 150% اليوم، ليقفز إلى المركز الثاني ضمن قائمة الأسهم الأفضل أداءً في مؤشر "إس آند بي 500" (S&P 500) لعام 2026. وبات السهم يحتل هذا الموقع المتميز بمفرده في قائمة تهيمن عليها شركات الذكاء الاصطناعي، ولا يسبقه سوى سهم شركة "سانديسك" (Sandisk).
{stock_us}(MRNA.US)
#stocks #moderna #SNDK #S&P500
{stock_us}(DELL.US)
هذا أمر مذهل. ارتفع سهم شركة "موديرنا" (Moderna) بنحو 150% اليوم، ليقفز إلى المركز الثاني ضمن قائمة الأسهم الأفضل أداءً في مؤشر "إس آند بي 500" (S&P 500) لعام 2026. وبات السهم يحتل هذا الموقع المتميز بمفرده في قائمة تهيمن عليها شركات الذكاء الاصطناعي، ولا يسبقه سوى سهم شركة "سانديسك" (Sandisk).
#stocks #moderna #SNDK #S&P500
#stocks #moderna #SNDK #S&P500
1
105
·
--
ສັນຍານກະທິງ
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
{future}(MRNAUSDT)
#moderna #MRNAon
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
1
363
·
--
ສັນຍານກະທິງ
ຢືນຢັນແລ້ວ
BIO+4,95%
MRNAUS-0,25%
704
·
--
ສັນຍານກະທິງ
قبل ٧ ساعات فقط جلبت لكم خبر رائع سيرفع سهم شركة $MRNA.US وكان السعر حينها 120 $ , وأخبرتكم أنه سيرتفع كما هو موضح 👇 والآن وصل سعر السهم 194 $ 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
{stock_us}(MRNA.US)
قبل ٧ ساعات فقط جلبت لكم خبر رائع سيرفع سهم شركة $MRNA.US وكان السعر حينها 120 $ , وأخبرتكم أنه سيرتفع كما هو موضح 👇 والآن وصل سعر السهم 194 $ 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
#stocks #MRNA #moderna #Stocks_DAB3
DAB3_1997
·
--
ສັນຍານກະທິງسهم $MRNA.US يرتفع بقوة بفضل النتائج الناجحة للقاح ضد سرطان الميلانوما. 💉
#stocks #stoksDAB3 #MRNA
#stocks #stoksDAB3 #MRNA
MRNAUS-0,25%
1
31
·
--
ສັນຍານກະທິງ
قفز سهم شركة "موديرنا" (MRNA) بنسبة 150% - محققاً أفضل أداء يومي في تاريخه - بعد أن أظهر لقاح للسرطان إمكانيةً في منع تكرار الإصابة بالورم الميلانيني. 📈 📈
{stock_us}(MRNA.US)
#stocks #stocksDAB3 #stockDAB3 #moderna
قفز سهم شركة "موديرنا" (MRNA) بنسبة 150% - محققاً أفضل أداء يومي في تاريخه - بعد أن أظهر لقاح للسرطان إمكانيةً في منع تكرار الإصابة بالورم الميلانيني. 📈 📈
#stocks #stocksDAB3 #stockDAB3 #moderna
#stocks #stocksDAB3 #stockDAB3 #moderna
MRNAUS-0,25%
1
43
·
--
ຢືນຢັນແລ້ວ
🚨 موديرنا وميرك تعلنان تقدّمًا كبيرًا في لقاح شخصي لعلاج السرطان بتقنية mRNA
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
🚨 موديرنا وميرك تعلنان تقدّمًا كبيرًا في لقاح شخصي لعلاج السرطان بتقنية mRNA
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
1
590
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
{spot}(SPCXBUSDT)
$MRNAon
{alpha}(560x01486675da0764ee780ea7cb65c33062e9b2d28c)
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
1
134
·
--
ບົດຄວາມ
STOCKS | Moderna Surges 50% Premarket, Merck Gains 5.6%Moderna (MRNA.O) experienced a remarkable surge of 50% in premarket trading, according to Jin10, reflecting investor optimism and strong market confidence. The biotech company’s shares jumped significantly ahead of the regular trading session, signaling a major rally driven by positive developments or market sentiment.
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
STOCKS | Moderna Surges 50% Premarket, Merck Gains 5.6%
Moderna (MRNA.O) experienced a remarkable surge of 50% in premarket trading, according to Jin10, reflecting investor optimism and strong market confidence. The biotech company’s shares jumped significantly ahead of the regular trading session, signaling a major rally driven by positive developments or market sentiment.
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
1
160
·
--
ຢືນຢັນແລ້ວ
🚨 THIS IS WHY $MRNA.US IS EXPLODING! 📈
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
🚨 THIS IS WHY $MRNA.US IS EXPLODING! 📈
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
MRNAUS-0,25%
373
ເຂົ້າສູ່ລະບົບເພື່ອສຳຫຼວດເນື້ອຫາເພີ່ມເຕີມ
ເຂົ້າຮ່ວມກຸ່ມຜູ້ໃຊ້ຄຣິບໂຕທົ່ວໂລກໃນ Binance Square.
⚡️ ໄດ້ຮັບຂໍ້ມູນຫຼ້າສຸດ ແລະ ທີ່ມີປະໂຫຍດກ່ຽວກັບຄຣິບໂຕ.
💬 ໄດ້ຮັບຄວາມໄວ້ວາງໃຈຈາກຕະຫຼາດແລກປ່ຽນຄຣິບໂຕທີ່ໃຫຍ່ທີ່ສຸດໃນໂລກ.
👍 ຄົ້ນຫາຂໍ້ມູນເຊີງເລິກທີ່ແທ້ຈາກນັກສ້າງທີ່ໄດ້ຮັບການຢືນຢັນ.
ອີເມວ / ເບີໂທລະສັບ
ຫົວຂໍ້ທີ່ກໍາລັງນິຍົມ
1
#UniswapA16zSeekDeFiExemptionFromIllinoisCryptoTax
35,131 ຄັ້ງທີ່ເບິ່ງ
862 ກຳລັງສົນທະນາ
2
#HKDollarStablecoinHKDAPToLaunchOnSolana
25,538 ຄັ້ງທີ່ເບິ່ງ
553 ກຳລັງສົນທະນາ
3
#$1.5BInLeveragedCryptoBetsLiquidated
53,777 ຄັ້ງທີ່ເບິ່ງ
267 ກຳລັງສົນທະນາ
4
#TrezorSaysCryptoBilisSoldWalletMayContainMaliciousComponents
4,703 ຄັ້ງທີ່ເບິ່ງ
83 ກຳລັງສົນທະນາ
5
#KOSPIFalls3.53%BackBelow6000
70,994 ຄັ້ງທີ່ເບິ່ງ
1,154 ກຳລັງສົນທະນາ
6
#AmazonSharesFallAbout7%InPremarketTrading
33,232 ຄັ້ງທີ່ເບິ່ງ
631 ກຳລັງສົນທະນາ
7
#USMidtermElections
277,575 ຄັ້ງທີ່ເບິ່ງ
2,414 ກຳລັງສົນທະນາ
8
#StrategySTRCReaches$99.95ForFirstTimeIn165Days
35,771 ຄັ້ງທີ່ເບິ່ງ
96 ກຳລັງສົນທະນາ
9
#BinanceWillListPredictPREDICT
107,969 ຄັ້ງທີ່ເບິ່ງ
1,450 ກຳລັງສົນທະນາ
10
#SwitzerlandFirstSpotBitcoinETFExpectedToTradeInNovember
3,428 ຄັ້ງທີ່ເບິ່ງ
115 ກຳລັງສົນທະນາ